DCF Advisers’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-3,500
| Closed | -$462K | – | 92 |
|
|
2025
Q1 | $462K | Sell |
3,500
-96,257
| -96% | -$12M | 0.22% | 70 |
|
|
2024
Q4 | $8.33M | Sell |
99,757
-750
| -0.7% | -$61.6K | 4.03% | 4 |
|
|
2024
Q3 | $7.35M | Hold |
100,507
| – | – | 2.94% | 6 |
|
|
2024
Q2 | $6.88M | Buy |
100,507
+3,650
| +4% | +$253K | 3.55% | 5 |
|
|
2024
Q1 | $6.7M | Hold |
96,857
| – | – | 3.3% | 8 |
|
|
2023
Q4 | $6.94M | Sell |
96,857
-10,300
| -10% | -$593K | 3.76% | 7 |
|
|
2023
Q3 | $5.58M | Hold |
107,157
| – | – | 3.04% | 7 |
|
|
2023
Q2 | $6.79M | Sell |
107,157
-11,443
| -10% | -$713K | 3.58% | 6 |
|
|
2023
Q1 | $6.42M | Sell |
118,600
-37,650
| -24% | -$1.82M | 3.93% | 7 |
|
|
2022
Q4 | $8.27M | Sell |
156,250
-9,749
| -6% | -$489K | 5.59% | 4 |
|
|
2022
Q3 | $7.72M | Sell |
165,999
-40,589
| -20% | -$2.12M | 4.99% | 4 |
|
|
2022
Q2 | $11.8M | Sell |
206,588
-31,912
| -13% | -$1.81M | 7.02% | 1 |
|
|
2022
Q1 | $14.6M | Sell |
238,500
-120,500
| -34% | -$6.26M | 6.39% | 2 |
|
|
2021
Q4 | $18.8M | Sell |
359,000
-20,000
| -5% | -$840K | 7.62% | 2 |
|
|
2021
Q3 | $14.1M | Buy |
379,000
+4,000
| +1% | +$139K | 6.24% | 2 |
|
|
2021
Q2 | $15.3M | Sell |
375,000
-49,500
| -12% | -$1.83M | 5.42% | 3 |
|
|
2021
Q1 | $14.4M | Hold |
424,500
| – | – | 6.26% | 1 |
|
|
2020
Q4 | $13.5M | Sell |
424,500
-2,500
| -0.6% | -$65.7K | 5.57% | 2 |
|
|
2020
Q3 | $11M | Buy |
427,000
+1,500
| +0.4% | +$34.2K | 5.6% | 4 |
|
|
2020
Q2 | $10.9M | Sell |
425,500
-7,000
| -2% | -$142K | 6.11% | 3 |
|
|
2020
Q1 | $6.65M | Sell |
432,500
-35,573
| -8% | -$773K | 4.35% | 5 |
|
|
2019
Q4 | $16.1M | Buy |
+468,073
| New | +$5.62M | 10.17% | 1 |
|
Other funds holding ITCI
KIM
HNB
DCF Advisers's ITCI Position: Q2 2025 in Review
DCF Advisers sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 3,500 shares — an estimated $462K sold.
DCF Advisers first reported a position in ITCI in Q4 2019 and held it in 22 quarters. The position peaked at $18.8M in Q4 2021. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- DCF Advisers reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- DCF Advisers sold 3,500 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $462K.
- DCF Advisers first reported a position in Intra-Cellular Therapies Inc. in Q4 2019 and held it in 22 quarters.
- DCF Advisers's Intra-Cellular Therapies Inc. position peaked at $18.8M in Q4 2021.
- 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on DCF Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.